Further processing options
Survival outcome segregated by KRAS mutation status in newly diagnosed stage IV non-small cell lung cancer (NSCLC) patients (pts) treated with first-line chemotherapy.
Saved in:
Journal Title: | Journal of Clinical Oncology |
---|---|
Authors and Corporations: | , , , , , , , |
In: | Journal of Clinical Oncology, 30, 2012, 15_suppl, p. 7595-7595 |
Type of Resource: | E-Article |
Language: | English |
published: |
American Society of Clinical Oncology (ASCO)
|
Subjects: |